Blueprint Medicines Corporation (0HOJ.L)
USD 77.48
(-8.85%)
USD 77.48
(-8.85%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 702.83 Million USD | 472.61% |
| 2022 | 122.74 Million USD | 224.56% |
| 2021 | -98.54 Million USD | 83.44% |
| 2020 | -595.03 Million USD | -3207.75% |
| 2019 | -17.98 Million USD | 66.34% |
| 2018 | -53.44 Million USD | 91.87% |
| 2017 | -657.02 Million USD | -148.08% |
| 2016 | -264.84 Million USD | -66.82% |
| 2015 | -158.75 Million USD | -315.62% |
| 2014 | -38.19 Million USD | -4460.5% |
| 2013 | 876 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 297.21 Million USD | -44.26% |
| 2024 Q1 | 484.6 Million USD | -31.05% |
| 2024 Q2 | 685.57 Million USD | 41.47% |
| 2023 Q4 | 702.83 Million USD | 905.46% |
| 2023 Q1 | -51.51 Million USD | -141.97% |
| 2023 FY | 702.83 Million USD | 472.61% |
| 2023 Q2 | 40.67 Million USD | 178.95% |
| 2023 Q3 | 69.9 Million USD | 71.87% |
| 2022 FY | 122.74 Million USD | 224.56% |
| 2022 Q4 | 122.74 Million USD | 358.57% |
| 2022 Q3 | -47.46 Million USD | 27.86% |
| 2022 Q2 | -65.8 Million USD | -190.98% |
| 2022 Q1 | 72.32 Million USD | 173.4% |
| 2021 FY | -98.54 Million USD | 83.44% |
| 2021 Q3 | -469.72 Million USD | -4.71% |
| 2021 Q4 | -98.54 Million USD | 79.02% |
| 2021 Q1 | -610.29 Million USD | -2.57% |
| 2021 Q2 | -448.58 Million USD | 26.5% |
| 2020 Q2 | -195.53 Million USD | 30.25% |
| 2020 Q3 | -473.81 Million USD | -142.32% |
| 2020 FY | -595.03 Million USD | -3207.75% |
| 2020 Q4 | -595.03 Million USD | -25.58% |
| 2020 Q1 | -280.33 Million USD | -1458.35% |
| 2019 Q3 | 8.27 Million USD | -50.11% |
| 2019 Q1 | 20.2 Million USD | 137.81% |
| 2019 Q4 | -17.98 Million USD | -317.49% |
| 2019 Q2 | 16.57 Million USD | -17.97% |
| 2019 FY | -17.98 Million USD | 66.34% |
| 2018 Q1 | -117.87 Million USD | 82.06% |
| 2018 FY | -53.44 Million USD | 91.87% |
| 2018 Q2 | -101.58 Million USD | 13.82% |
| 2018 Q3 | -63.31 Million USD | 37.67% |
| 2018 Q4 | -53.44 Million USD | 15.59% |
| 2017 Q3 | -45.33 Million USD | 46.0% |
| 2017 Q2 | -83.95 Million USD | -68.3% |
| 2017 Q4 | -657.02 Million USD | -1349.3% |
| 2017 FY | -657.02 Million USD | -148.08% |
| 2017 Q1 | -49.88 Million USD | 81.17% |
| 2016 Q3 | -66 Million USD | 34.01% |
| 2016 FY | -264.84 Million USD | -66.82% |
| 2016 Q4 | -264.84 Million USD | -301.28% |
| 2016 Q2 | -100.02 Million USD | 10.67% |
| 2016 Q1 | -111.96 Million USD | 29.47% |
| 2015 Q1 | -41.64 Million USD | -9.03% |
| 2015 FY | -158.75 Million USD | -315.62% |
| 2015 Q2 | -181.08 Million USD | -334.83% |
| 2015 Q3 | -167.81 Million USD | 7.33% |
| 2015 Q4 | -158.75 Million USD | 5.4% |
| 2014 Q1 | 1.98 Million USD | 0.0% |
| 2014 Q4 | -38.19 Million USD | 0.0% |
| 2014 FY | -38.19 Million USD | -4460.5% |
| 2013 FY | 876 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 782.69% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 2351.453% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -254.851% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -2104.284% |
| bluebird bio, Inc. | 108.57 Million USD | -547.352% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 7895.43% |
| Imunon, Inc. | -4.69 Million USD | 15056.271% |
| Editas Medicine, Inc. | -87.11 Million USD | 906.782% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 94.533% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 66.499% |
| Myriad Genetics, Inc. | 88.1 Million USD | -697.771% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -296.411% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 2196.328% |
| Verastem, Inc. | -37.27 Million USD | 1985.391% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 91.465% |
| Waters Corporation | 1.96 Billion USD | 64.149% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 97.381% |
| Biogen Inc. | 6.28 Billion USD | 88.823% |
| Nektar Therapeutics | 210.24 Million USD | -234.302% |
| Perrigo Company plc | 3.32 Billion USD | 78.844% |
| Dynavax Technologies Corporation | 106.63 Million USD | -559.104% |
| Illumina, Inc. | 1.21 Billion USD | 42.106% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -9986.515% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 717.129% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -384.461% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -9679.268% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -85.568% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 9999.099% |
| Evolus, Inc. | 63.7 Million USD | -1003.215% |
| Adicet Bio, Inc. | -142 Million USD | 594.927% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 2009.673% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 2693.491% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -53.224% |
| FibroGen, Inc. | 56.76 Million USD | -1138.107% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 38.617% |
| OPKO Health, Inc. | 230.68 Million USD | -204.676% |
| Homology Medicines, Inc. | 18.43 Million USD | -3712.095% |
| Geron Corporation | 14.76 Million USD | -4661.439% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 55.666% |
| Exelixis, Inc. | -73.05 Million USD | 1062.13% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 1395.407% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 565.38% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 730.901% |
| Zoetis Inc. | 4.76 Billion USD | 85.241% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 451.733% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 7078.81% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 107.349% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 4923.195% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 33.335% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 27.421% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 619.081% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 49.102% |
| Insmed Incorporated | 721.62 Million USD | 2.603% |
| TG Therapeutics, Inc. | 17.86 Million USD | -3834.811% |
| Incyte Corporation | -3.17 Billion USD | 122.136% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 8.222% |